Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

but a US appeals court in 2020 reinstated the $235 million judgment against the generics manufacturer. Fast forward to February of this year, and the US Court of Appeals declined Teva's request to ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...

1 Day TEVA 1.97% DJIA 0.02% S&P 500 0.24% Health Care/Life Sciences 0.00% ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Teva Pharmaceutical is one of the leading global ... halt production and meaningfully hurt the firm's top line as well as brand reputation. However, we don't see this as a likely scenario.

On January 10, 2025, Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing agreement to commercialize EPYSQLI® (eculizumab-aagh), Samsung ...